ABEONA THERAPEUTICS INC.

8-K · form8-k.htm

0000318306

 2026-06-03
 2026-06-03

 iso4217:USD

 xbrli:shares

 iso4217:USD

 xbrli:shares

  

  

  

 UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 Washington,
DC 20549

  

 FORM
 8-K

  

 CURRENT
REPORT

 PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

  

 Date
of report (Date of earliest event reported): June 3, 2026

  

 ABEONA
THERAPEUTICS INC.

 (Exact
name of registrant as specified in its charter)

  

 Delaware
  
 001-15771

 83-0221517

 (State
 or other jurisdiction of
 incorporation)

  
 (Commission

 File
 Number)

  
 (I.R.S.
 Employer

 Identification
 No.)

  

 6555
Carnegie Ave , 4th Floor

 Cleveland ,
 OH 44103

 (Address
of principal executive offices) (Zip Code)

  

 (646)
 813-4701

 (Registrant’s
telephone number, including area code)

  

 N
/A

 (Former
name or former address, if changed since last report)

  

 Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):

  

 ☐
 Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  
  

 ☐
 Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  
  

 ☐
 Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))

  
  

 ☐
 Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 Securities
registered pursuant to Section 12(b) of the Act:

  

 Title
 of Each Class
  
 Trading
 Symbol
  
 Name
 of each exchange on which registered

 Common
 Stock, $0.01 par value
  
 ABEO
  
 The
 Nasdaq Capital Market

  

 Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging
growth company ☐

  

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

  

  

  

  

  

 Item
8.01. Other Events

  

 On
June 3, 2026, Abeona Therapeutics Inc. (the “Company”) participated in a pre-Investigational New Drug application (“Pre-IND”)
meeting with the U.S. Food and Drug Administration (“FDA”) regarding ABO-701, a recently licensed radically novel engineered
T-cell therapy, targeting Prostate-Specific Membrane Antigen to treat prostate cancer. While official minutes of the meeting have not
yet been received, we believe the meeting was constructive and continues to target submission of an IND application for ABO-701 in 2027,
consistent with our previously stated timeline.

  

 We
can provide no assurance that the FDA will not require additional studies, data, or information before accepting an IND submission for
ABO-701, or that any IND submission, if submitted, will be accepted by the FDA or result in authorization to commence clinical trials.
Our development plans remain subject to ongoing evaluation and may be revised based on, among other things, feedback received from the
FDA, results of preclinical studies, manufacturing considerations, and other factors.

  

 Cautionary
Note Regarding Forward-Looking Statements

  

 This
Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements
regarding the Company’s expectations with respect to the timing of the IND submission for ABO-701, the Company’s clinical
and regulatory development plans, and other statements that are not historical facts. These forward-looking statements are based on the
Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking statements, including, but not limited to: the Company’s ability
to successfully advance ABO-701 through preclinical development; the timing, scope, and outcome of regulatory interactions, including
receipt of official minutes from the Pre-IND meeting; the FDA’s acceptance of any IND submission; the Company’s ability to
access additional financial resources or its financial flexibility to reduce operating expenses if required; the Company’s ability
to obtain additional equity funding from current or new stockholder; and other risks and uncertainties described in the Company’s
filings with the Securities and Exchange Commission (the “SEC”), including the “Risk Factors” section of the
Company’s most recent Annual Report on Form 10-K and subsequent periodic reports. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this report. The Company disclaims any obligation to update such statements to
reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

  

  

  

  

 SIGNATURE

  

 Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

  

  
 Abeona Therapeutics Inc.

  
 (Registrant)

  
  
  

  
 By:
 /s/
 Joseph Vazzano

  
 Name:
 Joseph
 Vazzano

  
 Title:

 Chief
 Financial Officer

  

 Date:
June 4, 2026